Shopping Cart
- Remove All
- Your shopping cart is currently empty
Azintuxizumab vedotin (ABBV-838) is an antibody-drug conjugate (ADC) that targets a specific epitope of CD2 subset 1, a cell-surface glycoprotein found on multiple myeloma cells [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Azintuxizumab vedotin (ABBV-838) is an antibody-drug conjugate (ADC) that targets a specific epitope of CD2 subset 1, a cell-surface glycoprotein found on multiple myeloma cells [1]. |
In vitro | Azintuxizumab vedotin (ABBV-838) is an antibody-drug conjugate (ADC) composed of a humanized recombinant immunoglobulin G1κ targeting a unique epitope of CD2 subset 1 (CS1, also known as SLAMF7). It is linked to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline linker, demonstrating potent cytotoxic activity against CS1-expressing cancer cells [1]. |
In vivo | Azintuxizumab vedotin (ABBV-838) demonstrated single-agent antitumor activity in a mouse model xenografted with human multiple myeloma [1]. |
Alias | ABBV-838 |
Cas No. | 1826819-58-2 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.